Phase II study of iproplatin (CHIP, JM-9) in advanced testicular cancers progressing after prior chemotherapy

Eur J Cancer Clin Oncol. 1988 Aug;24(8):1345-8. doi: 10.1016/0277-5379(88)90226-x.

Abstract

Twenty-two patients with advanced testicular cancer received iproplatin at a dose of 180-240 mg/m2 every 4 weeks. All the patients progressed or recurred after chemotherapy including cisplatin. The most severe toxicity was thrombocytopenia with two toxic deaths after a first cycle of 240 and 180 mg/m2 respectively. Nausea and vomiting were almost universal but mild in intensity. One renal failure occurred 6 weeks after the first cycle while the tumor was progressing. No antitumor activity was observed in this heavily pretreated population of patients.

MeSH terms

  • Adult
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Drug Evaluation
  • Humans
  • Leukocyte Count
  • Male
  • Middle Aged
  • Organoplatinum Compounds / adverse effects
  • Organoplatinum Compounds / therapeutic use*
  • Platelet Count
  • Teratoma / blood
  • Teratoma / drug therapy*
  • Testicular Neoplasms / blood
  • Testicular Neoplasms / drug therapy*
  • Thrombocytopenia / chemically induced

Substances

  • Antineoplastic Agents
  • Organoplatinum Compounds
  • iproplatin